13FGuru
Sign in with Google Sign in with Discord

NYSE · Health Care

EDWARDS LIFESCIENCES CORP EW

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.

Sources StockAnalysis company profile stockanalysis.com
Industrial Specialties

Company profile

Business mix

  • It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system.
  • The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name.
  • It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within medical devices?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 2 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 46.58 FCF 2.2% Buyback 1.88%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Viking Global Investors Andreas Halvorsen 0.2% $87.9M 2026-03-31
Wedgewood Partners David Rolfe 2.8% $13.7M 2026-03-31

Recent trading changes over the last 3 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 2 Last 3 13F filing periods
Net reducers 1 Last 3 13F filing periods
Unchanged holders 0 Share count unchanged
Increase amount $97.1M Estimated from net added shares
Reduction amount $565,765 Estimated from net reduced shares
Net share change / base shares +502.3% +1,208,298 / 240,556
Viking Global Investors Andreas Halvorsen 3 filing periods
13F 2025-09-30 Filed 2025-11-14
New Shares - 13F value change +$238.7M
13F 2025-12-31 Filed 2026-02-17
Sold out Shares -100.0% 13F value change -$238.7M
13F 2026-03-31 Filed 2026-05-15
New Shares - 13F value change +$87.9M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 0 Last 3 periods +1,097,578 (New) Total shares 1,097,578 Value $87.9M
Wedgewood Partners David Rolfe 3 filing periods
13F 2025-09-30 Filed 2025-11-14
Minor increase Shares 3.7% 13F value change +$105,454
13F 2025-12-31 Filed 2026-02-17
Minor reduction Shares -2.1% 13F value change +$1.1M
13F 2026-03-31 Filed 2026-05-15
Minor reduction Shares -5.5% 13F value change -$1.7M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 178,034 Last 3 periods -7,065 (-4.0%) Total shares 170,969 Value $13.7M
Bridgewater Associates Ray Dalio 2 filing periods
13F 2025-06-30 Filed 2025-08-13
Major increase Shares 611.6% 13F value change +$30.3M
13F 2025-09-30 Filed 2025-11-13
Major reduction Shares -59.5% 13F value change -$20.8M
Settlement As of 13F 2025-09-30 · Filed 2025-11-13
Base shares 62,522 Last 3 periods +117,785 (+188.4%) Total shares 180,307 Value $14.0M

Recent mentions

No public mentions.